SGN-CD228A

N/A

Report date: 2024/12/30 16:57:32

Base Information

Drug NameSGN-CD228A

Drug Alias NameSGN-CD228A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > β-glucuronide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized +[4]

Mechanisms of ActionTubulin polymerisation inhibitorsApoptosis stimulantsAnti-Melanotransferrin

TargetsMelanotransferrinTubulin

Therapy Area/IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesItalyUnited Kingdom +[5]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc

Active IndicationsN/A

Inactive IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6]

Other Information

ATC CodeN/A